• Executed Joint Development and Sales Agreement with Black Diamond Structures for Anteo X™ product in the US
• Achieved 10-fold manufacturing scale-up of Ultranodeâ„¢ anode material for Wyon AG's commercial cell evaluations
• Ultranodeâ„¢ X reached a new performance milestone of over 1,000 cycles at 80% capacity retention

In the December 2025 quarter, AnteoTech focused on expanding its existing product sales pipeline and accelerating business growth through new joint product development strategic partnerships. Key highlights include: Advanced Battery Technologies - Executed a Joint Development and Sales Agreement with US-based Black Diamond Structures to commercialize a joint Anteo X™/Molecular Rebar™ carbon nanotube product, with customer trials expected in February 2026. Achieved a 10-fold manufacturing scale-up of Ultranodeâ„¢ anode material for Wyon AG's commercial cell evaluations, and reached a new Ultranodeâ„¢ X performance milestone of over 1,000 cycles at 80% capacity retention. Life Sciences - Received a US$185,000 order from the Serum Institute of India and are evaluating a new AnteoBindâ„¢ activated ELISA plate product with them. Completed internal studies demonstrating significant cost savings and performance benefits of AnteoBindâ„¢ NXT compared to Tosyl chemistry in CLIA applications. Corporate - Completed a A$3.5 million capital raise to support sales growth initiatives and strategic partnership development across the business. The company ended the quarter with A$1.4 million in cash and no debt, with a pro-forma cash balance of A$4.9 million post the capital raise.

The company is focused on sales conversion in the current quarter, with the capital raise providing the 'runway' to convert its sales pipeline and new opportunities. The company expects the capital raise, combined with sales revenue and anticipated R&D rebate, to fund AnteoTech for the 2026 calendar year.